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INTRODUCTION 
Phenothiazines and other older antipsychotics drugs are 
being replaced by atypical antipsychotics. Atypical 
antipsychotics have a low risk of adverse extra pyramidal 
effect. The effectiveness against negative and positive 
symptoms of schizophrenia is attributed to their high 
affinity to 5HT2A and D4 receptor and also antagonistic 
action against alpha adrenergic, muscarnic& H1 and D2  
receptor
1
. Weight gain is common with Phenothiazines, 
Haloperidal, Thioxanthenes and Atypical antipsychotics 
like olanzapine, Clozapine. Weight gain is less common 
with Risperidone, Quetiapine Ziprasidone which are also 
atypical antipsychotics. Psychiatric patients need long 
term treatment with antipsychotics. Weight gain 
produced by antipsychotics may increase the risk of new 
onset Type2Diabetes mellitus
2
. Weight gain and 
development or exacerbation of Diabetes mellitus are 
serious issues that have forced clinicians to vigilantly 
follow up their patient’s metabolic profile to prevent 
serious consequences
3
.Studies have shown that use of 
risperidone in non diabetic schizhophrenic patients cause 
increase in the levels of fasting blood sugar levels from 
the baseline values .Hence this study stresses the 
monitoring of the fasting blood sugar during the 
treatment with risperidone. Many drugs cause diabetes 
mellitus and these are antipsychotics risperidone, 
olanzepine, clozapine in particular, and also other drugs 
like thiazide, B blockers, corticosteroids phenytoin 
sodium, tacrolimus ,  estrogen ,progesterone preparation 
and certain antidepressents.
4
 US regulators have 
proposed that 6 antipsychotics medication can increase 
the risk of impaired glucose tolerance and diabetes.  
These drugs are risperidone ,olanzepine , clozapine,  
quetiapine,ziprazidone,aripiprazole
5
 .Hence it was 
decided to conduct a study using risperidone in non 
diabetic psychiatric patients to find out if risperidone 
really causes changes in glucose tolerance, and has been 
designed accordingly. 
In this study already known diabetics and those 
diagnosed to have diabetes mellitus at the time of study 
were not included   because this study is to find out the 
effect of risperidone on blood sugar level who are having 
normal blood sugar level . If it is found out Risperidone 
produces Carbohydrate intolerence ,then the study could 
also be conducted on diabetics. 
 
 
 
 
ABSTRACT  
Aim & Objective: This study was designed to evaluate the metabolic effects of risperidone in patients with psychiatric illness 
treated with risperidone. 
Method: Thirty non-diabetic patients with Psychiatric illness (e.g. schizophrenia, manic phase of bipolor disorder based on 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) inducted in this study. These Patients did not 
receive any drug that would alter the blood sugar levels and also risperidone for at least four weeks prior to the initiation of the 
study. All the patients who were inducted in this study receive the mean dose of 4mg/day (range 2-8 mg) of risperidone for 
eight weeks, depending upon the clinical condition. The patients fasting, post prandial blood sugar and weight gain were 
evaluated at the baseline and then at four weeks and at eight weeks. 
Results: Thirty patients completed the study. The mean fasting blood sugar level was increased from 87.5mg/dL (baseline) to 
101.7 mg/dL at week 8 (P<0.001).The mean post prandial blood sugar was increased from111.68 mg/dl to147.88 mg/dl at week 
8 (p<0.001).There was also statistically significant weight gain with a increase in mean weight of59.16 kg to59.96 kg 
(p=0.001). The 8-week study showed that fasting blood sugar and postprandial blood sugar levels may increase in psychiatric 
patients receiving risperidone .There was also definite weight gain. No serious adverse events were reported. 
Conclusion: Measuring and monitoring fasting & postprandial blood sugar before the initiation and during the treatment with 
risperidone is suggested.  
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METHODOLOGY 
Study design:        Prospective, non comparative, open  
                              label study 
Place of study:      Dept of Psychiatry Government    
                             Stanley  medical college & Hospital.  
                             Chennai-1 
Study population:   30 
Study duration   :    8 weeks per patient 
Study period       :   November2012_April2013 
Inclusion criteria: 
1. All psychiatric patients who would benefit from 
risperidone. 
( e.g. schizophrenia, manic phase of bipolor disorder) 
2. Both sexes 
3. Age: 30-65years 
4. Patient without preexisting Diabetes mellitus / 
hypertention 
5. Psychiatric patients with near normal dietary intake 
Exclusion criteria: 
1. All old cases who are already on antipsychotics 
2. Those who are on diabetes mellitus/hypertension 
treatment 
3. Age: less than 30 years or more than 65 years 
4. Those with other systemic illness 
5. Acute uncontrollable cases of psychosis  
 After obtaining institutional ethical committee approval, 
thirty adult non diabetic patients with psychiatric illness 
(based on diagnostic and statistical manual of mental 
disorders, fourth edition criteria) were enrolled after 
obtaining informed consent and with the consent of legal 
guardian in this study. Subjects were between30_65 
years .Patients did not receive  any other antipsychotics 
or any other medication that could affect blood sugar 
levels (e .g) corticosteroids, B blockers, sulfonylureas, 
insulin, metformin, antidepressants ,etc for two weeks 
prior to initiation of the study and during the study 
period. Patients were received a mean of 4mg per day of 
risperidone for 8 weeks (Range of 2mg_8mg). Before 
starting therapy patient’s body weight, fasting blood 
sugar, postprandial blood sugar were recorded. 
The blood sugar levels were monitored at beginning of 
the study, 4 weeks   and at 8 weeks and reports were 
analyzed.  Results were presented asmean ± standard 
error. Results were analyzed using paired sample t test. 
Differences were considered significant when P value of 
<0.05. 
 Sex distribution: 
Table 1: shows the sex distribution among the study 
patients. 
 Frequency Percent Valid 
Percent 
Valid Male 20 62.0 62.0 
 Female 10 38.0 38.0 
 Total 30 100.0 100.0 
 
 
Figure1:  Bar diagram representing the percentage of sex 
distribution 
 Mean age of the participants were 52. Among this sixty 
two percent were male and thirty eight percent were 
female. Twenty males and ten females completed the 
study. 
 
 
 Mean fasting blood sugar level: 
Table 2: Shows the increase in mean fasting blood sugar level from baseline to eight  weeks. 
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 Mean Std. Deviation Minimum Maximum 
FBS_BL 87.56 8.650 60 98 
FBS_4w 94.56 5.870 76 100 
FBS_8w 101.76 4.809 86 110 
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Figure 2: Shows the Bar diagram representing the 
increase in the mean fasting    blood sugar level 
FBS-BL  _Fasting blood sugar-baseline 
FBS-4W - Fasting blood sugar-4
th
 week 
FBS-8W_ Fasting blood sugar-8
th
 week 
The mean FBS level was increased from87.56 mg/dl 
(baseline) to 94.56mg/dl at 4week and 101.76mg/dl at 
8weeks.The FBS levels at 8 weeks were significantly 
different from baseline FBS levels (p<0.001)        
 Mean postprandial blood sugar: 
Table 3: Shows the increase in mean post prandial blood 
sugar level. 
 Mean 
Std. 
Deviation Minimum Maximum 
PPBS_BL 111.68 7.366 90 120 
PPBS_4w 127.12 8.253 100 140 
PPBS_8w 147.88 7.411 136 170 
 
 
Figure 3: Bar diagram representing the mean increase in 
the mean  postprandial blood sugar level. 
PPBS-BL _Fasting blood sugar-baseline 
PPBS-4W - Fasting blood sugar-4
th
 week 
PPBS-8W_ Fasting blood sugar-8
th
 week 
The mean PPBS was increased from111.68 mg/dl 
(baseline) to127.12mg/dl at 4week and 147.88 mg/dl at 
8week.The PPBS level at 8week were significantly 
different from baseline PPBS level (p<0.001)  
Mean body weight: 
Table 4: Represents the mean increase in the body weight 
from baseline to 8week 
 Mean 
Std. 
Deviation Minimum Maximum 
BW_BL 59.16 6.693 46 69 
BW_4w 59.49 6.703 46 69 
BW_8w 59.96 6.718 46 69 
 
Figure 4: Bar diagram represents the mean increase in the 
body weight 
BW-BL _ Body weight baseline 
BW-4W – Body weight-4th week 
BW-8W_ Body weight-8
th
 week 
The patient’s Bodyweight was increased from59.16 
(baseline) to59.49 at4 weeks and59.96 at 8weeks.The 
weight gain was statistically significant ( p=0.001) 
DISCUSSION: 
In this study the effect of   risperidone on blood glucose 
level in non diabetic patients of psychiatric illness 
showed there was significant increase in both fasting and 
post prandial blood glucose level at the end of 4weeks 
and at the end of 8 weeks. Though there is increase in 
both FBS and PPBS level in patients treated with 
risperidone, at the end of 4week and at the end of 
8week,the increases are well within normal limits.  There 
was also statistically significant increase in body weight 
as shown in the table. 
The mechanism by which risperidone causes increase in 
blood sugar level was not fully understood. However the 
proposed mechanisms are; weight gain, insulin resistence 
increase in leptins concentration and glucose transport 
impairment 
6
. 
Therefore regular monitoring of blood glucose before 
starting risperidone to prevent further complication is 
necessary. 
The studies show that there is definite increase in FBS, 
PPBS in patients who have given risperidone .As noted 
already all the patients were non diabetics. 
The effect of risperidone in blood sugar level in patients 
who are preexisting diabetics has not been studied till 
now. In such cases risperidone and other antipsychotics 
as mentioned in the initial part of the study, may 
aggravate preexisting diabetics, when risperidone is 
given to treat the psychiatric illness. 
This may interferes with control of blood glucose level 
and it may be necessary to increase the dosage of anti 
diabetic drugs. In this study it has been shown 
risperidone definitely impairs glucose tolerance. Only 
further studies can establish the role of risperidone in 
interfering   glucose tolerance. 
From this study it has also transpired that blood sugar 
levels should be estimated in all the patients receiving 
risperidone, if not, in all the patients at least in those who 
are potentially diabetics .Since atypical antipsychotics 
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becoming popular blood sugar monitoring also becoming 
essential. Since the drug also causes weight gain, only 
further studies can prove, if   risperidone causes weight 
gain in diabetics also. 
Some anti diabetics (sulfonylureas) cause weight gain, so 
combined effects of anti diabetics and risperidone also 
should be evaluated. Such studies will establish the link 
between risperidone and rise in blood sugar level and 
weight gain. 
In this present study, patients are receiving different 
doses of risperidone ranging from 2mg to 8 mg , where 
another study is required ,in such a way that all the 
patients in study group are administered a fixed dose of 
risperidone every day. This can be done by careful 
selection.  
But this study also has limitation, like it has been studied 
only on very small groups   and also for very short 
period. 
CONCLUSION 
Risperidone definitely causes increase in blood sugar 
level. In this study this has been shown in non diabetic 
patients. Patients on risperidone should undergo frequent 
monitoring of blood sugar levels and it become essential 
in patients with preexisting   diabetes mellitus. Glucose  
tolerance test should  be done at regular intervals  in  
patients   who are receiving   risperidone. 
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